The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Allopurinol 100‐300 mg daily showed no clear difference in withdrawal due to adverse effects compared with febuxostat 80 mg daily (moderate certainty).
Allopurinol 100‐300 mg daily showed no clear difference in serious adverse effects compared with febuxostat 80 mg daily (moderate certainty).
Allopurinol 100‐300 mg daily showed no clear difference in acute gout attacks compared with febuxostat 80 mg daily (low certainty).
Allopurinol 100‐300 mg daily may leads to lower proportion achieving target serum urate compared with febuxostat 80 mg daily (low certainty).
Branched‐chain amino acids (BCAA) showed no clear difference in mortality Clinically compared with control (moderate certainty).
Branched‐chain amino acids (BCAA) leads to lower hepatic encephalopathy Psychometric and clinical assessments compared with control (high certainty).
Branched‐chain amino acids (BCAA) showed no clear difference in nausea and diarrhoea Clinically compared with control (low certainty).